发明名称 |
Modified polynucleotides for the production of biologics and proteins associated with human disease |
摘要 |
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. |
申请公布号 |
US8999380(B2) |
申请公布日期 |
2015.04.07 |
申请号 |
US201313791922 |
申请日期 |
2013.03.09 |
申请人 |
Moderna Therapeutics, Inc. |
发明人 |
Bancel Stephane;Chakraborty Tirtha;de Fougerolles Antonin;Elbashir Sayda M.;John Matthias;Roy Atanu;Whoriskey Susan;Wood Kristy M.;Hatala Paul;Schrum Jason P.;Ejebe Kenechi;Ellsworth Jeff Lynn;Guild Justin |
分类号 |
C12N15/85;A61K38/17;C07K14/47;C07K14/62;A61K48/00;A61K31/7115;C12N9/88;A61K9/127;C12N15/11;C07K14/705;C07K14/505;C07K14/535;C12N9/64;C12N9/10;C12N9/00;C12N9/42;C12N15/87;C12P13/04;A61K38/45;C07K14/005;C12N9/16;C12N9/24;C12N15/52;C07K14/435;C12P21/00;A61K38/00 |
主分类号 |
C12N15/85 |
代理机构 |
DT Ward PC |
代理人 |
DT Ward PC ;Ward Donna T.;Bryan Jennifer F. |
主权项 |
1. An isolated polynucleotide comprising;
(a) a first region of linked nucleosides, said first region encoding a polypeptide of interest, said polypeptide of interest is SEQ ID NO: 1089; (b) a first flanking region located at the 5′ terminus of said first region comprising at least one 5′ terminal cap; (c) a second flanking region located at the 3′ terminus of said first region comprising a 3′ tailing sequence of linked nucleosides; andwherein at least one of said linked nucleosides of (a) comprises at least one modification as compared to the chemical structure of an A, G, U or C ribonucleoside. |
地址 |
Cambridge MA US |